THE IMMUNOLOGIC DOUBLET OF LENALIDOMIDE PLUS OBINUTUZUMAB IS HIGHLY ACTIVE IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA, RESULTS OF A PHASE I/II STUDY. (June 2017) - Fowler, N.H.; Samaniego, F.; Turturro, F.; Neelapu, S.; Forbes, S.; Westin, J.; Fayad, L.; Fanale, M.; Feng, L.; Arafat, J.; Neal, E.; Hagemeister, F.; et al.